**BMJ Open**

**Effects of flow rate on transnasal pulmonary aerosol delivery of bronchodilators via high-flow nasal cannula for patients with COPD and asthma: protocol for a randomised controlled trial**

Jie Li,1 Jian Luo,2 Yibing Chen,3 Lixing Xie,3 James B Fink1,4

**ABSTRACT**

**Introduction** Both in vitro and in vivo radiolabelled studies on nebulisation via high-flow nasal cannula showed that inhaled dose decreases as the administered gas flow increases. In our previous in vitro study, we investigated the effects of the ratio of gas flow to subject’s peak inspiratory flow (GF:IF) on the aerosol deposition, which increased as the GF:IF decreased, with an optimal GF:IF between 0.1 and 0.5 producing a stable ‘lung’ deposition in both quiet and distressed breathing. Thus, we aim to validate our in vitro findings in subjects with reversible airflow limitations by assessing their response to inhaled bronchodilator.

**Methods and analysis** This is a single-centre, randomised controlled trial. Subjects with chronic obstructive pulmonary disease or asthma with positive response to 400μg albuterol via metered dose inhaler and valved holding chamber will be enrolled and consented. After a washout period (1–3 days), subjects will be randomly assigned to inhale albuterol with one of three gas flows: 50 L/min, GF:IF=1.0 and GF:IF=0.5. In each arm, subjects will inhale 2 mL saline, followed by escalating doubling doses (0.5, 1, 2 and 4 mg) of albuterol in a fill volume of 2 mL, delivered by a vibrating mesh nebuliser via heated nasal cannula set up at 37°C. An interval of 30 min between each dose of albuterol, with spirometry measured at baseline and after each inhalation. Titration will be terminated if forced expiratory volume in 1 s improvement is <5%, or adverse event is observed.

**Ethics and dissemination** This trial has been approved by the Ethic Committee of People’s Liberation Army General Hospital, Beijing, China (no. S2018-200-01). The results will be disseminated through peer-reviewed journals, national and international conferences.

**Trial registration number** NCT03739359; Pre-results.

**INTRODUCTION**

High-flow nasal cannula (HFNC) delivers medical gas at a flow exceeding patient inspiratory flow demand.1 For hypoxaemic patients, it has been shown to improve oxygenation and help avoid intubation,2 and for patients with chronic obstructive pulmonary disease (COPD), HFNC has been demonstrated to reduce work of breathing, improve ventilation and alleviate hypercapnia.3

In clinical practice, many medications are preferred to be aerosolised to the lower airway or alveoli to have direct effects on the target organ. HFNC has recently become a feasible, effective and comfortable route to deliver aerosolised medication,3–10 and two recently published studies reported that regular dose of bronchodilator via HFNC at 30–35 L/min could generate similar bronchodilation...
effects as jet nebuliser in stable COPD patients. Clinical observations found paediatric patients were more comfortable and less anxious while inhaling bronchodilator via HFNC.

Multiple in vitro studies have reported a range of influential factors associated with the delivery efficacy using HFNC system, such as delivery gas type, density and flow rate, nebuliser type and placement, breathing pattern, size of nasal cannula and type of humidification system, of which the administered gas flow rate is believed to play a critical role. Inhaled dose is found to increase when the administered gas flow rate decreases in quiet breathing. With the extreme flow low setting (5 L/min) for adults via ‘HFNC’ system with vibrating mesh nebuliser, the delivery efficiency was found to be comparable as standard jet nebuliser in pharmacokinetic studies. Our previous bench study further explored the effects of the ratio of nasal cannula gas flow to patient inspiratory flow (GF:IF), which was found to be the primary predictor of inhaled dose, while the ratio of 0.1–0.5 produced higher and more consistent inhaled dose than that of ratio at 1.0 or above in quiet breathing. Therefore, to validate our in vitro findings, we propose a randomised controlled trial to compare the bronchodilation effects of inhaled albuterol in three groups receiving different flow rates: (1) 50 L/min, which is a common HFNC flow setting in adult subjects; (2) gas flow is set to match subject inspiratory flow (GF:IF=1.0), which meets the minimal requirement of gas flow by HFNC definition that the gas flow at least equals subject inspiratory flow demand and (3) gas flow is set at 50% of subject inspiratory flow (GF:IF=0.5). The hypothesis is that inhaled dose will be greater in subjects receiving GF:IF=0.5 than the two higher flow arms. Subject bronchodilation effect, represented by improvement in forced expiratory volume in 1 s (FEV₁), is directly related to the inhaled dose of bronchodilator up to full or plateau bronchodilator response. Escalating doses of bronchodilator will be administered to each subject. As the bronchodilator (albuterol) has a steep response curve, we hypothesise that at the low dose of albuterol, response rate in the group of GF:IF=0.5 will be higher than that in the groups of GF:IF=1.0 and gas flow at 50 L/min. We will also compare the effective dose that subjects meet the response criteria, and we hypothesise that a lower effective dose of bronchodilator might be required in the group using higher gas flows.

METHODS
This is a randomised controlled trial, registered with ClinicalTrials.gov (NCT03739359). The report of the protocol followed the Standard Protocol Items: Recommendations for Interventionsal Trials guideline.

Study population
Stable subjects will be recruited from outpatients with COPD or asthma who demonstrate positive response during bronchodilator response testing in the pulmonary function test lab, People’s Liberation Army General Hospital, Beijing, China.

Inclusion criteria
Adult stable subjects with COPD or asthma with positive bronchodilator responses to four actuations (400 µg) of albuterol (Ventolin, GSK, Brentford, UK) via metered dose inhaler (MDI) with valved holding chamber (VHC) (OptiChamber Diamond, Philips, Andover, Massachusetts, USA) will be eligible for enrollment. A positive bronchodilator response is defined in accordance with American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines as follows: an increase in FEV₁ of ≥12% and absolute change ≥200 mL from baseline. COPD and asthma are diagnosed based on the standards recommended by the relevant guidelines.

Exclusion criteria
Subjects will be excluded if any of the following criteria are met: age ≥50 years; pregnancy; pulmonary exacerbation within 2 weeks before enrollment; reluctant to participate; inability to complete the follow-up spirometry after each bronchodilator inhalation; resting heart rate >100 bpm; resting systolic blood pressure >160 mm Hg or diastolic blood pressure >110 mm Hg.

Study procedures
For study diagram see figure 1.

Recruiting and consent process
Subjects who are eligible for the study will be approached by the study investigator (Y.C). The study purpose and procedure, as well as risks and benefits will be explained thoroughly to the individual subject in a quiet room. Consent forms will be given to subjects and they will have up to 3 days to consider if they are willing to participate in the study. Consent will be signed after they return and witnessed by the study investigator. Randomisation group will be assigned after consent is signed. Subjects will be informed that bronchodilator treatment needs to be withheld prior to testing, according to standard practice (immediate release theophylline needs to be withheld for 24 hours before the test, long-acting β2-agonist for 12 hours, short-acting β2-agonist for 6 hours and short-acting anticholinergic for 8 hours).

Randomisation and masking
A computer-based randomisation sequence will be generated before study commencement by an independent statistician. Randomisation will be assigned by permuted block methods using Fisher and Yates tables of random permutations.

Subjects will return to the pulmonary function test lab for randomisation within 1–3 days of initial screening to inhale saline and an escalating dose of albuterol administered by vibrating mesh nebuliser (VMN, Aerogen Solo, Aerogen Ltd., Galway, Ireland) via nasal cannula. Subjects will be randomly assigned to three groups of nasal oxygen...
cannula gas flow to inhale albuterol: 50 L/min, GF:IF=1.0 and GF:IF=0.5.

Randomisation will also be stratified by disease (asthma and COPD). A block size of six subjects will be constructed to reduce predictability and the probability of serious mid-block inequality in the planned interim analyses. Two series of sequentially numbered, sealed, opaque envelopes containing the treatment assignment will be opened when eligibility criteria are met. This can ensure the number of subjects with asthma and COPD are equal in the three groups. Nebulisation will be offered in a separate room, and both subjects and the pulmonary function test technician will be blinded to the group. Only the investigator who opens the opaque envelope and sets up the gas flow for the subject knows the group assignment, she will also collect the data.

**Bronchodilator delivery via HFNC**

A calibrated back pressure compensated air flowmeter will be attached via T-piece adapter with VMN at the inlet (dry side) of a heated humidifier (MR 850, Fisher & Paykel, Auckland, New Zealand). A single limb heated wire circuit will be attached to an adult HFNC (Optiflow, Fisher & Paykel, Auckland, New Zealand), with prong size chosen according to the diameters of subjects’ nostrils. Assigned gas flow will be set and confirmed by a mass flowmeter (4040, TSI, Shoreview, Minnesota, USA), and the heater will be turned on (for approximately 15 min) to achieve 37°C prior to connecting to subjects (figure 2).

Subjects will be seated in an upright position and instructed to perform relaxed tidal breathing via nose with mouth closed. Subjects’ vital signs will be continuously monitored including heart rate, cardiac rhythm, respiratory rate and blood pressure. Administration of 2 mL of albuterol will take 6–8 min. Spirometry will be performed at baseline, and after each nebulisation. HFNC will be removed from the subjects and the subjects will be required to sit quietly for 10–12 min before performing spirometry test.

**Prescreening bronchodilator delivery via MDI with VHC**

Albuterol MDI (Ventolin, 100 μg/puff) will be shaken and primed per label before use, and the primed MDI will be inserted into a VHC. Subjects will sit upright and be instructed to place the spacer mouthpiece into the mouth with sealed lips after a maximal exhalation. A slow and deep inhalation through VHC will be initiated immediately after one actuation of albuterol from the MDI is administered, followed by a breath hold of 5–10 s and a slow exhalation via nose. This whole process will be repeated three more times at a 60 s interval to achieve a total of four puffs.

**Spirometry test**

During screening and after randomisation, pulmonary spirometry will be measured at baseline, and after inhaling aerosol (saline and each dose of bronchodilator) via HFNC. To ensure the quality, all the tests will be completed using the same calibrated spirometer operated by the same pulmonary function technician.

**Determining peak inspiratory flow during quiet breathing**

Spirometry during tidal breathing will be firstly performed to determine subject’s peak inspiratory flow. Subjects will be required to rest for at least 10 min and then be coached to breathe normally via mouthpiece with nose clipped for at least 3 min or when the tidal breathing is
stabilised, followed by a 1 min recording. Mean values of the resting peak inspiratory flows for 1 min will be used as individual’s peak inspiratory flow.

**Forced vital capacity test**

A body plethysmograph (JAEGER-Vyaire, Mettawa, Illinois, USA) with daily calibration by a 3L syringe will be used to measure the FEV1 and forced vital capacity (FVC) according to the ATS/ERS standardised practices. Briefly, subjects will be seated uprightly and guided to complete the following three distinct phases: (1) maximal inspiration; (2) a ‘blast’ of exhalation and (3) continued complete exhalation until the volume-time curve shows no change in volume (<0.025L) for ≥1 s, and the subject has tried to exhale for ≥6 s. To meet the ATS/ERS acceptability and reproducibility criterion, a minimum of three acceptable FVC manoeuvres will be needed to ensure the difference between the two largest FVCs is <150 mL.

**Drug preparation**

The stock concentration of 2.0 mg/mL albuterol (Ventolin, 5 mg in 2.5 mL) diluted with normal saline to 1.0, 0.5 and 0.25 mg/mL. A total fill volume of 2.0 mL with each dose of 0.5, 1.0, 2.0 and 4.0 mg will be placed in nebuliser.

**Termination criteria**

Dose escalation will be terminated if any of the criteria is met: (1) adverse events are observed or reported including tachycardia, tremor, irregular heart rhythm, blood pressure increase >20% and headache; or (2) when improvement in FEV1 is <5% greater than a previous dose in which bronchodilator response is identified.

Any subject who experiences adverse events will be rested and monitored in general unit, until the subject’s recovery.

**Outcomes**

The primary outcome is to compare the response rate in three flow groups at each accumulative dose. The secondary outcome is to identify the cumulative dose of albuterol required across groups to produce positive bronchodilation response.

The bronchodilator response is determined by meeting any of the following criteria: (1) ATS/ERS criteria of positive response; (2) absolute value of FEV1 postbronchodilator via HFNC ≥ prescreening FEV1 postbronchodilator. ATS/ERS criteria of FEV1 increment is not the only criteria to decide if subject responds to bronchodilator, the reason is subjects’ baseline FEV1 may vary on daily basis. FEV1 increment might be less if baseline FEV1 is high. As long as FEV1 returns to prescreening FEV1 postbronchodilator, the response is still deemed as positive. The response rate is calculated by the percentage of subjects who meet the criteria in each group.

**Sample size calculation**

This study is a superiority study. Since all the recruited subjects are responders to 400 μg of bronchodilator via MDI+VHC and the inhaled dose of MDI+VHC is reported to be approximately 20% of emitted dose (80 μg). From our in vitro study, inhaled dose of bronchodilator via nasal cannula at GF:IF=0.5 was found to be approximately 20% of dose, compared with 3.5% with gas flow rate at 50 L/min. We hypothesise that a 20% inhaled dose of 0.5 mg in the group of GF:IF=0.5 would be 100 μg, which is >80 μg administered with MDI+VHC. In contrast, at 50 L/min with 3.5% lung dose an accumulative inhaled dose of 2.5 mg would provide an inhaled dose of 87.5 μg. We hypothesise that almost all subjects in the GF:IF=0.5 group would respond to albuterol at the accumulative inhaled dose of 1.5 mg. To calculate the sample size, with confidence level (α) of 95%, power (1–β) of 80% and margin (Δ) of 0.2, we assumed 80% of GF: IF=0.5 group will respond to cumulative dose of 1.5 mg albuterol, compared with 40% 50 L/min group. The number of subjects in each group will be 25 and the total number of subjects will be 75.

**Data collection**

Independent investigators will be allocated to record relevant data including demographic information (age, gender, height, weight, race, smoking history, diagnosis), baseline lung function via tidal breathing (tidal volume and peak inspiratory flow) and forced spirometry parameters (FEV1, FVC, PEF, FEF75, FEF75-25 and FEF25) before and after each dosage of bronchodilator inhalation.

**Statistical analysis**

For continuous variables, normality of distribution will be tested by the Kolmogorov-Smirnov test, and they will be presented as mean±SD or mean and IQR. The differences of forced spirometry parameters including FEV1, FVC, PEF, FEF75, FEF75-25 and FEF25 among the three flow groups will be tested by one-way analysis of covariance, whereas repeated measures analysis of variance will be used to compare the differences of the FEV1 improvement among different doses of bronchodilator within the same group. Categorical variables will be expressed as percentage and analysed by X2 test. A two-sided p value of <0.05 will be considered to be statistically significant for all tests. Data analysis will be conducted with SPSS software (SPSS V.23.0, Chicago, Illinois, USA).

The data for subjects who withdraw from the study (such as unwilling to continue the next dose) will be removed from data analysis, but will be reported in the supplement files.

**Patient and public involvement**

Patients and/or public were not involved in the study design.

**DISCUSSION**

Transnasal aerosol delivery via HFNC has become a popular route in the recent years, as for its benefits of patient’s comfort, convenience for drug delivery and the
continuum of HFNC. However, the aerosol deposition is impacted by many factors, in which flow rate especially the ratio of GF:IF plays a key role. In the retrospective report of using inhaled epoprostenol via HFNC to improve hypoxaemia, patients whose oxygenation was improved had HFNC flow rate decreased, while flow rate was raised in the deteriorated patients. It might be explained that decreased flow rate improved inhaled dose of epoprostenol, which resulted in better oxygenation. It could also be vice versa that gas flow rate was reduced because of improved oxygenation. However, the sequence of adjusting flow rate and patient’s response was not reported, it is difficult to identify the effects of flow rate adjustment on the drug delivery. Thus, to our knowledge, this is the first study to assess the influence of administered gas flow rate in relation to patient inspiratory flow on the clinical effects of transnasal aerosol delivery.

The dose escalation method used in this study will also help explore the effective dose in the three HFNC flow settings, which have clinical implications: (1) 50 L/min, the general HFNC flow setting in adult patients, especially those who require high flow to improve oxygenation/ventilation and also need aerosolised medication, such as inhaled epoprostenol to treat refractory hypoxaemia or inhaled bronchodilator to treat bronchospasm, decreasing flow with sacrifice of oxygenation/ventilation to serve aerosol delivery might not be realistic, but higher dose might be needed in order to elicit the effects, thus exploring the effective dose or starting dose is highly demanded; (2) GF:IF=1, the minimal flow setting per HFNC definition. Because the requirement to measure patient inspiratory flow, our study becomes the first study to measure patient inspiratory flow before using HFNC, the breathing pattern for stable patients with chronic pulmonary disease will be studied, this result will also benefit for the HFNC flow setting for those stable patients with domiciliary use of HFNC, which has been reported to improve patients’ mucociliary clearance and life quality score, with reduction in COPD exacerbation rates and hospital admissions. The results of effective bronchodilator dose can guide the dose for these patients who need to inhale bronchodilator when they are at home and 3) GF:IF=0.5, at this flow ratio, the benefits of high flow rate might be compromised, which means the FiO2 is not as accurate and consistent as it is supposed to be, due to the air entrainment. The effects of washing out dead space and positive airway pressure will also be sacrificed as well. Thus, the mode at this ratio should be described as low flow nasal cannula (LFNC). However, LFNC might serve those patients who just need a feasible and comfortable route to inhale aerosolised medication, such as inhaled epoprostenol for an extended periods of time to treat pulmonary hypertension, or patients who can tolerate temporary reduction on flow setting during HFNC in order to increase the inhaled dose, such as intermittent use of bronchodilator for patients with COPD or asthma, because the regular dose and volume (1–2 mL) of bronchodilator costs <10 min to complete nebulisation, reducing flow in such short term is unlikely to influence the long-term clinical benefits of HFNC. Therefore, our study would ultimately help to guide the clinical practitioners to choose appropriate gas flow according to the individual situations.

Reminiac et al reported that HFNC alone had limited bronchodilation effects, thus the first step in our study is inhaling saline via HFNC to assess its effects in our population. However, we anticipate this effect will be observed but minimal, due to two facts in our design: firstly, our patients will only use HFNC for inhaling aerosol, which means the time of using HFNC is only 6–8 min per dose, much shorter than 30 min in the study by Reminiac et al; secondly, there is 10–12 min interval between disconnection from HFNC and spirometry test, the bronchodilation effects caused by HFNC may attenuate in the interval.

The major limitation of this study is that we only evaluate the stable patients with known response to bronchodilator, thus the effective dose from our finding might not directly apply for the hospitalised patients with exacerbation or distressed breathing, among whom HFNC is more frequently used. However, as the first attempt, this study will still investigate the effective transnasal pulmonary dosing of albuterol in stable patients at different gas flows, which might provide an appropriate starting nebulisation dose for asthma and COPD in acute exacerbation receiving HFNC.

ETHICS AND DISSEMINATION

Recruitment and consent
Prospective, written consent will be obtained from all the participants.

Data collection, storage and access
Data will be sourced from forced expiratory capacity test results, electronic medical records and monitors. Data will be de-identified and entered into a secure, web-based electronic database.

Dissemination strategy
The results of the study will be presented in national and international conferences, and published via a peer-reviewed journal.

Author affiliations
1Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, Chicago, Illinois, USA
2Department of Pulmonary and Critical Care Medicine, Sichuan University West China Hospital, Chengdu, China
3Department of Respiratory and Critical Care Medicine, Pulmonary Function Test Lab, General Hospital of People’s Liberation Army, Beijing, China
4Aerogen Pharma Corp, San Mateo, California, USA

Acknowledgements The authors would like to thank Mr Rongshou Zheng, MPH from National Cancer Center, China to generate the randomisation sequence and provide statistical consultation.
Contributors JL conceived and designed the study, drafted and revised the manuscript. JLu participated in the study design and revised the manuscript. YC is the study principal investigator, recruited the subjects, supervised the study and revised the manuscript. LX supervised the study and revised the manuscript. JF designed the study and revised the manuscript.

Funding This research is funded by the National Center of Research on Clinical Geriatric Diseases, China (project grant NRCGD-PLAGH-2017003).

Competing interests Dr JBF is Chief Science Officer for Aerogen Pharma Corp and discloses relationships with Dance Biopharm.

Patient consent for publication Obtained.

Ethics approval This study was approved by the Ethic Committee of People’s Liberation Army General Hospital, Beijing, China (no. S0208-200-01, current approved protocol V2, 12 March 2019).

Provenance and peer review Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Helviz Y, Einav S. A systematic review of the high-flow Nasal Cannula for Adult Patients. Crit Care 2018;22:71.
2. Zhu Y, Yin H, Zhang R, et al. High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients with acute respiratory failure: a systematic review and meta-analysis of randomized controlled trials. BMC Pulm Med 2017;17:201.
3. Fraser JF, Spooner AJ, Dunster KR, et al. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. Thorax 2016;71:759–61.
4. Pisani L, Fasano L, Corcione N, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax 2017;72:373–5.
5. Ammar MA, Sasidhar M, Lam SW. Inhaled epoprostenol through noninvasive routes of ventilator support systems. Ann Pharmacother 2018;52:1173–81.
6. Bräunlich J, Wirtz H. Oral versus nasal high-flow bronchodilator inhalation in chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv 2018;31:248–54.
7. Reminiac F, Vecellio L, Bodet-Contentin L, et al. Nasal high-flow bronchodilator nebulization: a randomized cross-over study. Ann Intensive Care 2018;8:128.
8. Madney YM, Fathy M, Elberry AA, et al. Aerosol delivery through an adult high-flow nasal cannula circuit using low-flow oxygen. Respir Care 2019;64:453–61.
9. Morgan SE, Mosakowski S, Solano P, et al. High-flow nasal cannula and aerosolized β2 agonists for rescue therapy in children with Bronchiolitis: a case series. Respir Care 2015;60:e161–e165.
10. Baudin F, Buissone A, Vanel B, et al. Nasal high flow in management of children with status asthmaticus: a retrospective observational study. Ann Intensive Care 2017;7:55.
11. Dugernier J, Hesse M, Junetz T, et al. Aerosol delivery with two nebulizers through high-flow nasal cannula: a randomized cross-over single-photon emission computed tomography–computed tomography study. J Aerosol Med Pulm Drug Deliv 2017;30:349–58.
12. Bhashyam AR, Wolf MT, Marcinkowski AL, et al. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv 2008;21:181–8.
13. Perry SA, Kesser KC, Geller DE, et al. Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med 2013;14:e250–6.
14. Réminiac F, Vecellio L, Heuzé-Vourc’h N, et al. Aerosol therapy in adults receiving high flow nasal cannula oxygen therapy. J Aerosol Med Pulm Drug Deliv 2016;29:134–41.
15. Dailey PA, Harwood R, Walsh K, et al. Aerosol delivery through adult high flow nasal cannula with heliox and oxygen. Respir Care 2017;62:1186–92.
16. Li J, Gong L, Fink JB. The ratio of nasal cannula gas flow to patient inspiratory flow on trans-nasal pulmonary aerosol delivery for adults: an in vitro study. Pharmaceutics 2019;11:225.
17. Mazhar SH, Ismail NE, Newton DA, et al. Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation. Br J Clin Pharmacol 2008;65:334–7.
18. Chan AW, Tetzlaff JM, Altmann DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7.
19. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38.
20. Kaminsky DA, Wang LL, Bates JH, et al. Fluctuation analysis of peak expiratory flow and its association with treatment failure in asthma. Am J Respir Crit Care Med 2017;195:993–9.
21. Nawam SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9:55–70.
22. Li J, Zhong M. Comment: Inhaled epoprostenol through noninvasive routes of ventilator support systems. Ann Pharmacother 2019;53:326.
23. Hasani A, Chapman TH, McCool D, et al. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis 2008;5:61–6.
24. Nagata K, Kikuchi T, Horie T, et al. Domiciliary high-flow nasal cannula oxygen therapy for patients with stable hypercapnic chronic obstructive pulmonary disease. a Multicenter Randomized Crossover Trial. Ann Am Thorac Soc 2018;15:432–9.
25. Storgaard LH, Hockey HU, Laursen BS, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 2018;13:1195–205.